UNSPSC 51112002: Dasatinib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C22H26ClN7O2S.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RBZ1571X5H, chemically known as 5-thiazolecarboxamide, n-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)-1-piperazinyl)-2-methyl-4-pyrimidinyl)amino)- but generally known as dasatinib, which bears US NIH Compound Identifier 3062316. European Medicines Agency schedules Dasatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB23322.

UNSPSC 51112002 Dasatinib, a Commodity code, covers pharmaceutical products supplied through state and local cooperative purchasing contracts, specifically generic and brand-name medications distributed via authorized wholesalers to government facilities. State and local governments procure dasatinib and related pharmaceuticals through multistate cooperative purchasing alliances, individual state health agencies, and county health departments that aggregate demand across participating jurisdictions to negotiate volume pricing and standardized supply agreements with pharmaceutical manufacturers and distributors.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities in Minnesota and Oregon. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026. Evaluation emphasizes price competitiveness (75 percent), fixed pricing for the contract term (10 percent), EDI capability (5 percent), compliance with administrative fee data format requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must maintain commercial general liability insurance of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000, certify current Good Manufacturing Practices compliance and Drug Supply Chain Security Act compliance, and demonstrate pricing flexibility through flat price, net price formats, or WAC-minus structures. Contract awards may be sole, dual, or multi-awards based on therapeutic considerations and patient safety, with initial two-year terms and optional extensions.